30 closest matches · ranked by relevance
Warm Autoimmune Hemolytic Anemia · Cold Agglutinin Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 5; 5; 7; 6 Participants
Cold Agglutinin Disease
Primary: Part A: Percentage of Participants With Response to Treatment — 72.7; 15.0 percentage of participants — p=<0.001
Agglutinin Disease, Cold
Primary: Part A: Percentage of Participants With Response to Treatment — 54.2 percentage of participants
Cold Agglutinin Disease
Primary: Number of Patients Achieving a Response (R) at Week 24 — 8; 2 Participants
Gaucher Disease
Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…
Cold Contact Urticaria
Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001
Immune Thrombocytopenic Purpura
Primary: Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis
Blood Transfusion · Rhesus Isoimmunisation Due to Anti-D · Blood Group Antigen Abnormality
Primary: Occurrence of Alloanti-D Immunization in Asian-type DEL Recipients Transfused With RhD+ RBCs — 42; 12 Participants — p=< 0.001
Cold Agglutinin Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 7; 1 Participants
Upper Respiratory Tract Infections
Primary: Frequency of Influenza-like Illness — 54; 62; 16; 28 participants — p=0.25
Common Cold
Primary: Total Symptom Score (TSS) Over Days 2 to 4 (TSS2-4) — 6.390; 5.777 units on a scale — p=0.0895
Hyperbilirubinemia · Erythroblastosis, Fetal
Primary: Need of Exchange Transfusion — 6; 7 participants — p=0.765
Multiple Myeloma · Plasma Cell Neoplasm
Primary: Tolerance for Human Immune Globulin Intravenous (IGIV), as Reflected by the Number and Severity of Toxicity Incidents Occurring in Ten Patients Receiving at Least One…
Common Cold
Primary: Sum of All Symptoms in Viruspositive Persons — 52; 52; 54; 56 units on a scale — p=<0.037
Sickle Cell Disease · Anti-D Antibodies
Primary: Anti-D Recurrence — 0; 5 Participants
Common Cold
Primary: Reducing Symptoms of a Common Cold — 53; 53; 55; 54 units on a scale
Celiac Disease
Primary: Number of Participants for Which Treatment Was Concluded to be Safe — 6; 18; 4; 5 participants
Common Cold
Primary: Number of Days With at Least Moderate (i.e. Moderate or Severe) Common Cold Symptoms. — 7.6; 9.5 Number of days — p=0.023
Common Cold
Primary: Number of Participants With Rhinovirus-associated Illness Episodes — 63; 60 Participants
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Autoimmune Autonomic Ganglionopathy (AAG)
Primary: Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) — 42.5; -12.3 mmHg
Upper Respiratory Infection · Common Cold
Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml
Cold Urticaria
Primary: Percentage of Participants With Negative Ice Cube Provocation Test at Week 24 — 37.5; 40.5 percentage of participants — p=0.9492
Asthma
Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049
Influenza A H3N2 · Influenza A H1N1
Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants
Hemophilia A
Primary: Proportion of Subjects With Major Response, i.e. Inhibitor Level Falls to Less Than 5 BU/mL Between Weeks 6 to 22 and Remains Below 5 BU/mL at 5-7 Days Following…
Primary Immunodeficiency
Primary: Annual Rate of Occurrence of Serious Bacterial Infections (SBI) — 0; 0.01; 0; 0.03 Rate of events per subject per year
Primary Thrombocytopenia
Primary: Percentage of Responders — 80.6 Percentage of participants
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants